

**IN THE CLAIMS:**

*This listing of claims will replace all prior versions and listings of claims in the application:*

1. – 100. (Cancelled)

101. (New) An immunogenic composition comprising an autologous VEGF polypeptide impaired for receptor activation identified as SEQ ID NO: 21 or fragments thereof identified as SEQ ID NO: 27 to SEQ ID NO: 36 and SEQ ID NO: 77 to SEQ ID NO: 86; and at least one of the molecules described in:

- a) VEGFR2 polypeptide fragments identified as SEQ ID NO: 137 to SEQ ID NO: 146 and SEQ ID NO: 187 to SEQ ID NO: 196;
- b) VEGFR2 polypeptide fragments identified as SEQ ID NO: 137 to SEQ ID NO: 146 and SEQ ID NO: 187 to SEQ ID NO: 196, said composition being mixed with or incorporated into p64K protein of *Neisseria meningitidis*;
- c) VEGFR2 polypeptide fragments identified as SEQ ID NO: 137 to SEQ ID NO: 146 and SEQ ID NO: 187 to SEQ ID NO: 196, said composition being mixed with or incorporated into *Neisseria meningitidis* outer membrane derived VSSP;
- d) VEGFR2 polypeptide fragment identified as SEQ ID NO: 23;
- e) VEGFR2 polypeptide fragment identified as SEQ ID NO: 23, said composition being mixed with or incorporated into p64K protein of *Neisseria meningitidis*;

- f) VEGFR2 polypeptide fragment identified as SEQ ID NO: 23, said composition being mixed with or incorporated into *Neisseria meningitidis* outer membrane derived VSSP;
- g) VEGFR2 polypeptide fragment identified as SEQ ID NO: 25;
- h) VEGFR2 polypeptide fragment identified as SEQ ID NO: 25, said composition being mixed with or incorporated into p64K protein of *Neisseria meningitidis*; or
- i) VEGFR2 polypeptide fragment identified as SEQ ID NO: 25, said composition being mixed with or incorporated into *Neisseria meningitidis* outer membrane derived VSSP;

in single or fusion protein form, and optionally further comprising a pharmaceutically accepted adjuvant.

102. (New) An immunogenic composition comprising an oligonucleotide encoding for an autologous VEGF polypeptide impaired for receptor activation identified as SEQ ID NO: 21 or fragments thereof identified as SEQ ID NO: 27 to SEQ ID NO: 36 and SEQ ID NO: 77 to SEQ ID NO: 86, and at least one of the molecules described in:

- a) Oligonucleotides encoding for VEGFR2 polypeptide fragments identified as SEQ ID NO: 137 to SEQ ID NO: 146 and SEQ ID NO: 187 to SEQ ID NO: 196;
- b) Oligonucleotides encoding for VEGFR2 polypeptide fragments identified as SEQ ID NO: 137 to SEQ ID NO: 146 and SEQ ID NO: 187 to SEQ ID NO: 196, said composition being mixed with or incorporated into the p64K protein of *Neisseria meningitidis*;
- c) Oligonucleotides encoding for VEGFR2 polypeptide fragments identified as SEQ ID NO: 137 to SEQ ID NO: 146 and SEQ ID NO: 187 to

SEQ ID NO: 196, said composition being mixed with or incorporated into *Neisseria meningitides* outer membrane derived VSSP;

- d) Oligonucleotides encoding for a VEGFR2 polypeptide fragment identified as SEQ ID NO: 23;
- e) Oligonucleotides encoding for a VEGFR2 polypeptide fragment identified as SEQ ID NO: 23, said composition being mixed with or incorporated into p64K protein of *Neisseria meningitides*;
- f) Oligonucleotides encoding for a VEGFR2 polypeptide fragment identified as SEQ ID NO: 23, said composition being mixed with or incorporated into *Neisseria meningitides* outer membrane derived VSSP;
- g) Oligonucleotides encoding for a VEGFR2 polypeptide fragment identified as SEQ ID NO: 25;
- h) Oligonucleotides encoding for a VEGFR2 polypeptide fragment identified as SEQ ID NO: 25, said composition being mixed with or incorporated into p64K protein of *Neisseria meningitides*; or
- i) Oligonucleotides encoding for a VEGFR2 polypeptide fragment identified as SEQ ID NO: 25, said composition being mixed with or incorporated into *Neisseria meningitides* outer membrane derived VSSP;

in single or bicistronic vector form, and optionally further comprising a pharmaceutically accepted adjuvant.

103. (New) An immunogenic composition according to claim 101, wherein the adjuvant is selected from the group consisting of recombinant particle of Hepatitis B Core Antigen, recombinant particle of Hepatitis C Core Antigen, OPC protein, KLH protein, *Neisseria meningitides* p64k protein, or *Neisseria meningitides* outer membrane derived VSSP.

Applicants: Romero et al.  
Serial No.: 10/511,384  
Filed: October 15, 2004  
Response to Office Action Dated March 12, 2008  
Page 9 of 15

104. (New) An immunogenic composition according to claim 102, wherein the adjuvant is selected from the group consisting of recombinant particle of Hepatitis B Core Antigen, recombinant particle of Hepatitis C Core Antigen, OPC protein, KLH protein, *Neisseria meningitides* p64k protein, or *Neisseria meningitides* outer membrane derived VSSP.